Rakovina Therapeutics Finalizes Oversubscribed $4.9 Million Private Placement
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a pioneering biopharmaceutical company focused on advancing new cancer therapies through cutting-edge artificial intelligence (AI) technologies, has successfully closed its highly anticipated non-brokered private placement, raising gross proceeds of $4,905,150. This placement comprises $3,555,150 from equity units and $1,350,000 from convertible debenture units.
Details of the Private Placement
The private placement involved the sale of two main types of securities: equity units, referred to as “Units,” and convertible debenture units, called “Debenture Units.” The Units were priced at $0.05 each and each included one common share plus one purchase warrant entitled to acquire an additional common share at $0.10 for a duration of 24 months. The Debenture Units comprised one unsecured convertible debenture with a principal amount of $50,000 along with 100,000 warrants, each exercisable at $0.15 over the same period.
Investment and Financial Details
This financing strengthens Rakovina's capital structure while providing strategic resources to advance its innovative projects. Notably, insiders of the Company took part in this round, contributing $735,000 through the purchase of 14,700,000 Units, which constitutes a related party transaction as per the regulatory standards.
The Company is committed to complying with all regulations and ensuring no new insiders were created nor changes in control occurred from this financing initiative. The securities issued will be subject to a statutory hold period of four months and one day in accordance with applicable securities laws, further safeguarding the integrity of the investment process.
Future Plans and Strategic Goals
Rakovina Therapeutics is preparing to execute a significant consolidation of shares through a proposed 10-for-1 ratio. This measure is integral to enhancing shareholder value and is set to align with the growth strategy as the Company moves forward post-private placement. The pre-consolidation amounts discussed will be adjusted once this consolidation takes effect.
CEO’s Insights on Growth and Investor Relations
In expressing gratitude towards investors, Jeff Bacha, the Executive Chairman, conveyed his excitement regarding the substantial backing from existing and new shareholders. He emphasized that this financing marks a critical milestone in Rakovina's evolutionary journey, enabling essential advancements in its development programs. This newfound capital will facilitate further alignment with prospective partners in the U.S. market, paving the way for future collaborations and growth.
Use of Proceeds from the Private Placement
The funds raised will be utilized to bolster multiple growth initiatives within Rakovina Therapeutics, primarily focusing on enhancing its proprietary AI-driven drug discovery tools. The development efforts will also concentrate on increasing awareness and visibility among institutional investors, particularly within the U.S. capital markets.
Collaborations in Investor Relations and Marketing
To further advance its market position, Rakovina has engaged Fairfax Partners Inc. as its Investor Relations (IR) partner and has initiated collaboration with Machai Capital Inc. for corporate communications. Fairfax will roll out a comprehensive three-month IR program designed to elevate Rakovina's visibility to new heights. This program is not only aimed at traditional IR efforts but will also include targeted online marketing campaigns.
Machai Capital's expertise in branding, SEO, digital marketing, and social media will significantly contribute to raising awareness regarding Rakovina Therapeutics. Both firms are set to receive substantial budgets to ensure the effectiveness of these marketing efforts.
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a dedicated research firm that specializes in the pursuit of innovative cancer treatments. With a forward-looking approach utilizing advanced AI technologies, the Company aims to establish a pipeline of DNA-damage response inhibitors. This goal focuses on advancing drug candidates into human clinical trials in alliance with notable pharmaceutical partners.
Utilizing proprietary platforms such as Deep-Docking™ and Enki™, Rakovina is committed to optimizing drug efficacy and speeding up the process, marking a notable shift in oncological treatment development.
Frequently Asked Questions
What was the total amount raised in the private placement?
Rakovina Therapeutics raised a total of $4,905,150 through its private placement.
How does the private placement benefit Rakovina Therapeutics?
The funds will support the development of innovative cancer therapies and enhance investor visibility in capital markets.
What are the types of securities sold in the placement?
The private placement consisted of Units and Debenture Units, with each Unit including common shares and purchase warrants.
Who were the financial advisors for this placement?
Rakovina paid finder’s fees to Canaccord Genuity Corp., Ventum Financial Corp., Haywood Securities Inc., and Leede Financial Inc.
What is Rakovina's strategy moving forward?
The Company plans to implement a share consolidation and continue growing its market presence while refining its drug development processes.
